The MarketWatch News Department was not involved in the creation of this content. -- AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a ...

Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.

Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, ...

AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its ...